Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
Bretylium tosylate is an intravenous antiarrhythmic agent approved by Pfizer in 1986 for the treatment of life-threatening ventricular arrhythmias. It works through sympathomimetic and antifibrillatory mechanisms to restore normal cardiac rhythm. This injectable medication is administered to patients in acute cardiac care settings experiencing severe arrhythmias unresponsive to first-line therapies.
With lifecycle stage LOE approaching and competitive pressure at 30%, the brand team is likely in maintenance/harvest mode with reduced headcount and focus on defending existing volume.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on bretylium represents a career transition opportunity rather than growth; roles emphasize operational excellence, account retention, and institutional relationships in hospital/emergency settings. This is suitable for professionals seeking stability and deep domain expertise in cardiac care over rapid career advancement.
Worked on BRETYLIUM TOSYLATE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.